Manuel Corpas is a lecturer in Genomics at the University of Westminster, London, and serves as Scientific Director of Cambridge Precision Medicine, a company associated with the Cambridge University business accelerator (ideaSpace). Manuel is an expert in providing clinical genomics interpretation services to healthcare institutions. He is also a visiting tutor/lecturer at the University of Cambridge and director of the expert course in clinical genetics and personalized medicine at the International University of La Rioja.
He has more than 60 scientific publications in international journals and one book. He graduated in Biomedical Sciences from the University of Navarra, with a master’s and PhD in Bioinformatics from the University of Manchester, and 3.5 years of postdoctoral experience at the Sanger Institute, Cambridge, UK.
.png)
2011 at Universidade NOVA de Lisboa, Portugal. From 2011 to 2012, he worked as a postdoctoral researcher in proteomics at Prof. Chris Overall laboratory, University of British Columbia (UBC), Vancouver, Canada. In 2012, Ricardo moved to the Leiden University Medical Hospital, The Netherlands, after being awarded a Marie Curie Individual Postdoctoral Fellowship. There, he joined Prof. Liam McDonnell laboratory to develop and apply mass spectrometry imaging-based methods to study biomolecular changes in the brain associated with migraine. Ricardo moved to the UK in 2015 to join the Proteomics Department at Immunocore Ltd, Abingdon, which he now leads. At Immunocore, most of his work focuses on the identification of targets for the development of immunotherapies against cancer, autoimmune, and infectious diseases. He is interested in the application of omics technologies to profile the immunopeptidome and understand disease-specific mechanisms to help developing improved therapeutic strategies.
Dr. Arijit Mukhopadhyay is a researcher in Human Genetics & Genomics with over 23 years of research experience (17 years post PhD). Currently, he is a Reader in Human Genetics at the University of Salford, Manchester, United Kingdom. He has worked on a variety of diseases and contributed to fundamental understanding of genetic aetiology. Currently, he is interested in epi-transcriptomic changes as biomarkers for precision health. Till to date, he has published 69 peerreviewed publications and supervised 15 PhD students (h-index 28; ~2700 citations).
I am a group leader at Barts Cancer Institute, where my goal is to stop cancer before it starts. I believe that the root cause of most cancers is not a problem of genetic disruption, but a corruption of the cell memory and reignition of embryogenesis programmes, and the gross genomic aberrations are a downstream consequence. Our research focuses on the transition of healthy, normal cells to cancerous cells through the process of aging, because age by far the biggest factor in developing cancer. Specifically, we use in vivo mouse models and perform epigenetic editing of healthy and cancerous cells in order to understand the root causes of cancer initiation and proliferation, with the ultimate goal of chemoprevention.
Dr. Alessandro Riccombeni has more than 14 years of international experience in genomics research, product development, and business strategy across the US and EMEA. Riccombeni has led the development of cloud platforms for bioinformatics and commercial services for gene editing. He started his career in research, leading projects in Oncology and Infection Biology for 6 years before moving into industry.
Amy is the Business Support Scientist for UKI region working as part of the EMEA Clinical and Scientific Affairs team at Bionano. She gained a PhD in Molecular and Cellular Biology at the University of Glasgow after which she gained a post-doctoral researcher position at The Beatson Institute for Cancer Research in the lab of Professor Hing Leung. After completing her post-doc she joined Bionano and has been responsible for the running of projects across the NHS, Research lab and Biotech companies.
Started my career on the Human Genome Project at the Sanger Institute in Cambridge, UK. Made a team leader at Sanger. Then moved to Cancer Genomics at Cancer Research UK (CRUK) Cambridge Institute, where they had 3 Genome Analyzers – some of the first in the world. Headed own lab in London at the London Research Institute at CRUK where he started genomics side the project TracerX (Lung Cancer Study) which became the Francis Crick Institute.I am also as a founder member of a Genomics Core Manager Consortium called the London Genomics Network (LGN) https://londongenomicsnetwork.org/, where we discuss new technologies & experiences.
Paul joined Alnylam in March 2018 and is responsible for leading the Discovery and Translational Research function. He has overall responsibility for new target identification/validation, biomarkers and all preclinical drug discovery programs. Building on his depth of prior experience, he also leads the Alnylam Human Genetics center which focuses on identification of new drug targets from large genotype-phenotype datasets.Paul has over 18 years of biotech and pharma experience. He joined Alnylam following a tenure at Amgen and deCODE genetics where he held roles of increasing responsibility. Most recently he was Director of the Translational Systems Biology group and led a large team that was focused on making discoveries from human genetics to influence target selection.
Ping Zhang is a senior postdoctoral scientist in statistical functional genomics at the University of Oxford. He received his PhD in cancer biology from Heidelberg University in Germany and has particular expertise in modelling the interaction between germline, somatic variants and epigenetic changes. His current research is focused on using human induced pluripotent stem cells and primary macrophages together with multidisciplinary approaches in functional genomics to discover the genetic components and causal mechanisms driving heterogeneity of pathogenesis in autoimmune and infectious diseases.
Dr Williams graduated from Cardiff University in 1996 with a BSc in Genetics and later, in 2005 a PhD focusing on the genetics of schizophrenia. In 2013 he moved to UCL Great Ormond Street Institute of Child Health and began working on the genomics of rare paediatric diseases where he ran the GOSgene group. In 2019 Dr Williams returned to Cardiff University to take up a post a senior lecturer in bioinformatics where his work is focused on the use of Omics techniques to better understand the genomic basis of rare diseases.
Dr Georgia Tsagkogeorga is a Principal Scientist in Bioinformatics at STORM Therapeutics Ltd and at the Milner Therapeutics Institute of the University of Cambridge. She currently works in the fields of RNA modification and drug discovery, with a focus on RNA-modifying enzymes as a novel class of therapeutic targets in oncology and other disease areas. Georgia has an academic background in phylogenomics and evolutionary genomics, with over 10 years of experience in computational analysis of multi-modal “omics” data, including genomics, transcriptomics and proteomics data sets from a wide variety of animal model systems (chordates, mammals, human). For a full list of publications, please see: https://scholar.google.co.uk/ citations?user=JtR_cyoAAAAJ&hl=en
Saumyaa is a senior scientist at AstraZeneca, Sweden. She focuses on assessing and ensuring the safety of AstraZeneca’s Gene Therapy and Engineered Cell Therapy drug candidates. Before this role, she served as a single-cell omics specialist at Astra. She has a background in Immunology and NGS, from her academic research in the USA. She did her Ph.D. in Immunology and her postdoctoral research in Onco-Immunology at Stanford University.
Manuel Corpas is a lecturer in Genomics at the University of Westminster, London, and serves as Scientific Director of Cambridge Precision Medicine, a company associated with the Cambridge University business accelerator (ideaSpace). Manuel is an expert in providing clinical genomics interpretation services to healthcare institutions. He is also a visiting tutor/lecturer at the University of Cambridge and director of the expert course in clinical genetics and personalized medicine at the International University of La Rioja.
He has more than 60 scientific publications in international journals and one book. He graduated in Biomedical Sciences from the University of Navarra, with a master’s and PhD in Bioinformatics from the University of Manchester, and 3.5 years of postdoctoral experience at the Sanger Institute, Cambridge, UK.
.png)
Ignacio Mazon works as Strategic Account Manager for Arima Genomics in Europe, a company that develops innovative 3D genomics solutions that drive discovery in genomics and improve human health.. Ignacio graduated from the University of Oviedo in Biology and Biochemistry, and he holds a PhD degree in Biology from the University of Rostock in Germany. His thesis focused on the Identification of susceptibility genes in EAE, a mouse model of Multiple Sclerosis and he also was a post-doctorate research fellow at the National Hellenic Research Foundation where he studied the genetic-epigenetic mechanisms of epithelial mesenchymal transition (EMT) and metastasis in colorectal cancer. Ignacio has extended business development and management experience in the fields of epigenetics and Next generation sequencing.
With more than 20 years in the Genomics industry, I have a passion and expertise in transcriptomics having been involved with the emerging technologies of QPCR, microarrays, RNA-Seq, single cell genomics and for the last 18 months with in-situ spatial transcriptomics.
.png)
Prof Cutillas graduated with a PhD in 2004 from UCL. His studies (completed in the laboratories of Prof Mike Waterfield, Prof Rainer Cramer and Prof Al Burlingame) were on a project that investigated kidney physiology. He then completed postdoctoral training at the Ludwig Institute for Cancer Research (UCL branch) in Bart Vanhaesebroeck’ s lab. In 2007, he became lecturer at the Centre for Cell Signalling and in 2010 he was promoted to Senior Lecturer. After a period in the Centre for Haemoto-Oncology, leading the Cell Signalling and Proteomics Group, he moved to the Centre for Genomics and Computational Biology and promoted to full professor in 2020. Prof Cutillas has fellowships from the Alan Turing institute (since 2018) and DERI (since 2021). His work as led to 101 research articles (25 as corresponding and 8 as first author) and 15 review articles with an overall i10 index of 87. He is the main inventor in 6 patents and academic co-founder of 2 spin-out companies.
Natalie joined Bio-Techne in September 2019 and is a Spatial Biology Specialist, supporting the Advanced Cell Diagnostics ISH assays. Previously she was an Account Manager at Leica Biosystems for their Core Histology & Advanced Staining portfolios looking after clinical and research customers. Prior to Leica, Natalie spent twelve years as a Biomedical Scientist working in NHS Cellular Pathology laboratories and completed her Master’s in Pathological Sciences from the University of Sheffield during this time
Eleanor Wheeler in an Associate Principal Scientist at AstraZeneca. She completed her PhD in statistical genetics at the University of Cambridge and has over 15 years of experience using common and rare genetic variation to understand the genetic contribution to disease. Eleanor’s background is in academia, studying the genetics of diabetes, obesity and related quantitative traits within and across diverse ancestry groups. Most recently she has been working with proteomic data generated using both the SomaLogic and Olink platforms to identify genetic variants influencing protein levels and using those results to try to identify genes influencing disease and prioritise drug targets.
Silvia Wuertenberger joined PreOmics in 2022 as Product Manager for BeatBox. She interacts with customers and internal teams alike to provide customers with the best possible product solution for their needs in sample preparation. She holds a PhD in Biology from Eberhard-Karls-University Tübingen and is an expert in protein biochemistry and analytical technologies to measure protein attributes in vitro and in cellular contexts. Prior to PreOmics, Silvia gained experience in commercialization and development of biophysical tools for drug discovery at NanoTemper Technologies.
Manuel Mayr is the British Heart Foundation (BHF) Professor for Cardiovascular Proteomics. He then moved to London to undertake a PhD on combining proteomics and metabolomics. Upon completion of his PhD in 2005, he achieved promotion to Professor at King’s College London in 2011. In 2017, he has been awarded a BHF Personal Chair. His group uses proteomics in combination with other -omics technologies to integrate biological information in disease-specific networks that drive pathophysiological changes. He has published more than 275 peer review scientific papers. His academic achievements have been recognised by the inaugural Michael Davies Early Career Award of the British Cardiovascular Society (2007), the inaugural Bernard and Joan Marshall Research Excellence Prize of the British Society for Cardiovascular Research (2010), the Outstanding Achievement Award by the European Society of Cardiology Council for Basic Cardiovascular Science (2013) and most recently the President’s Distinguished Lecture of the International Society for Heart Research (2022).
Dr Deniz received her PhD in 2014 with Professor Modesto Orozco from Barcelona University, where her research focused on nucleosome positioning in yeast. For her postdoctoral training, Dr Deniz joined Dr Miguel Branco’s group at Queen Mary University of London to investigate the epigenetic regulation of transposons in early development and cancer. She uncovered the novel roles of two key enzymes in the epigenetic pathway that regulate transposons in mammalian development and demonstrated the first examples of transposons that can act as oncogenic enhancers in leukaemia. In 2021, she joined Imperial College London as a Research Fellow to establish her own research programme, funded by Imperial and AstraZeneca. In 2022, she was awarded a Cancer Research UK Career Development Fellowship and joined the Centre for Haemato-Oncology at Barts Cancer Institute, Queen Mary University of London. Her lab focuses on the roles of transposable elements in cancer genome.
Nikolina Nakić is a Senior Director, Head of V2G2F Computational Biology in Genomic Sciences and GSK’s Science Lead for Open Targets. She received training in Biomedicine and Computational Biology at IDIBAPS Barcelona and Imperial College London. Her focus is on leveraging big data for translating genetic signals into targets, using omics, functional genomics, and statistical methods. She regularly teaches at Imperial College London, as an Honorary Lecturer.
2011 at Universidade NOVA de Lisboa, Portugal. From 2011 to 2012, he worked as a postdoctoral researcher in proteomics at Prof. Chris Overall laboratory, University of British Columbia (UBC), Vancouver, Canada. In 2012, Ricardo moved to the Leiden University Medical Hospital, The Netherlands, after being awarded a Marie Curie Individual Postdoctoral Fellowship. There, he joined Prof. Liam McDonnell laboratory to develop and apply mass spectrometry imaging-based methods to study biomolecular changes in the brain associated with migraine. Ricardo moved to the UK in 2015 to join the Proteomics Department at Immunocore Ltd, Abingdon, which he now leads. At Immunocore, most of his work focuses on the identification of targets for the development of immunotherapies against cancer, autoimmune, and infectious diseases. He is interested in the application of omics technologies to profile the immunopeptidome and understand disease-specific mechanisms to help developing improved therapeutic strategies.
